Kamada Announces Extension of GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] Supply and Distribution Agreement with Takeda Through 2021 and Expected Transition of GLASSIA Manufacturing to ...
Kamada Ltd. - Ordinary Shares (KMDA)
Last kamada ltd. - ordinary shares earnings: 2/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
kamada.com/investors.php
Company Research
Source: GlobeNewswire
Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million Based on Current GLASSIA U.S. Sales and Forecasted Growth, Kamada Projects to Receive Royalties from Takeda in the Range of $10 Million to $20 Million Per Year from 2022 to 2040 Kamada Anticipates Utilizing Most of its Manufacturing Plant’s Available Capacity Following the Transfer of GLASSIA Manufacturing to Takeda Through Anticipated Growth of its Other Products, and Opportunities to Initiate Production of Additional Plasma-Derived Products REHOVOT, Israel, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today the extension of its strategic supply agreement with Takeda for GLASSIA® [Alpha1-Proteinase Inhibitor (Human)]. Kamada will now continue to produce GLASSIA for Takeda through 2021. Based on the extended agreement, Kamada projects that tota
Show less
Read more
Impact Snapshot
Event Time:
KMDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KMDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KMDA alerts
High impacting Kamada Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
KMDA
News
- Kamada Ltd. (NASDAQ: KMDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance [Yahoo! Finance]Yahoo! Finance
- Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial GuidanceGlobeNewswire
- Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024GlobeNewswire
- Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
KMDA
Earnings
- 5/8/24 - Miss
KMDA
Analyst Actions
- 5/9/24 - HC Wainwright
KMDA
Sec Filings
- 5/8/24 - Form 6-K
- 5/1/24 - Form 6-K
- 3/6/24 - Form 6-K
- KMDA's page on the SEC website